医学
托法替尼
肝损伤
耐火材料(行星科学)
胃肠病学
内科学
前瞻性队列研究
不利影响
肝移植
抢救疗法
肝损伤
胆红素
肝衰竭
自身抗体
外科
肝病学
疾病严重程度
肝酶
作者
J Gu,Yuan Wang,Xiaoyu Wang,Yingying Yan,Fei Pei,Tianyu He,Chunlei Zhang,Jun Li,Wenhui Wang
摘要
Drug-induced liver injury (DILI) with severe DRESS carries high mortality, yet rescue therapies for corticosteroid-refractory cases remain undefined. We hypothesized that JAK inhibition could reverse refractory liver injury by targeting the underlying cytokine storm. In this prospective proof-of-concept study, consecutive patients with severe DRESS-associated DILI refractory to corticosteroids (persistent/worsening liver injury) received oral tofacitinib rescue. Key assessments were the normalisation of liver biochemistries. Despite initial corticosteroids, all four patients exhibited progressive severe injury (median peak ALT 1126 U/L). Tofacitinib rapidly reversed liver injury in all cases. Transaminases normalised or near-normalised (median: 48 days), total bilirubin normalised, and cutaneous symptoms resolved completely. Notably, baseline positive autoantibodies seroconverted to negative. No severe adverse events occurred (median follow-up: 274 days). Tofacitinib shows promise as a rescue strategy for corticosteroid-refractory DILI with severe DRESS. The rapid recovery underscores the JAK-STAT pathway's pathogenic role in this setting.
科研通智能强力驱动
Strongly Powered by AbleSci AI